Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Always Active
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

GARDP Request for Proposal Zoli POP PK modeling

Closing date: 25.08.2023

GARDP has entered in collaboration agreement with Innoviva Specialty Therapeutics (IST), formerly known as Entasis therapeutics for the development of Zoliflodacin. Zoliflodacin (ETX0914) is a new promising option to address the risk posed by drug[1]resistant gonorrhoea. The drug belongs to a new class of antibiotics with a novel mode of action that inhibits bacterial deoxyribonucleic acid (DNA) replication and demonstrated in vitro activity against drug resistant strains of NG. It offers many of the preferred characteristics for gonorrhoea therapy, including single dose oral therapy, low rate of side effects. It is currently the only novel drug targeting exclusively gonorrhoea, in late-stage development / pre-introduction phase in the world. The purpose of this RFP is to find a Contract Research Organization (CRO) that can provide pharmacometrics support for Zoliflodacin new drug approval. The overarching goal of this project is to select a safe and efficacious dose of Zoliflodacin as supportive evidence to the Phase 3 trial results.

 

If you are interested to receive complete documentation of this RFP, please send a request to: RFP_Procurement@gardp.org.

 

Closing date: August 25th 2023